KLP Kapitalforvaltning AS Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

KLP Kapitalforvaltning AS bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 30,700 shares of the biopharmaceutical company’s stock, valued at approximately $924,000.

Several other large investors have also recently bought and sold shares of the stock. Hillsdale Investment Management Inc. acquired a new stake in TG Therapeutics in the 4th quarter worth $4,521,000. 1620 Investment Advisors Inc. bought a new position in TG Therapeutics during the fourth quarter valued at about $128,000. Teacher Retirement System of Texas raised its holdings in TG Therapeutics by 18.3% in the 4th quarter. Teacher Retirement System of Texas now owns 43,565 shares of the biopharmaceutical company’s stock valued at $1,311,000 after acquiring an additional 6,742 shares in the last quarter. Xponance Inc. lifted its position in shares of TG Therapeutics by 14.7% in the 4th quarter. Xponance Inc. now owns 10,318 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 1,326 shares during the period. Finally, Cibc World Markets Corp acquired a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $393,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.50% of the company’s stock.

TG Therapeutics Stock Down 1.1 %

Shares of NASDAQ TGTX opened at $39.43 on Tuesday. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The business has a fifty day moving average of $34.57 and a two-hundred day moving average of $30.50. The stock has a market cap of $6.19 billion, a PE ratio of -394.26 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TGTX shares. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.